AR032390A1 - Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad - Google Patents

Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad

Info

Publication number
AR032390A1
AR032390A1 ARP020100053A ARP020100053A AR032390A1 AR 032390 A1 AR032390 A1 AR 032390A1 AR P020100053 A ARP020100053 A AR P020100053A AR P020100053 A ARP020100053 A AR P020100053A AR 032390 A1 AR032390 A1 AR 032390A1
Authority
AR
Argentina
Prior art keywords
inhibit
treatment
endometry
gestagens
infertility
Prior art date
Application number
ARP020100053A
Other languages
English (en)
Spanish (es)
Inventor
Christa Hegele-Hartung
Holger Hess-Stumpp
Henning M Beier
Claudia Krusche
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/801,925 external-priority patent/US20020143000A1/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR032390A1 publication Critical patent/AR032390A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ARP020100053A 2001-01-09 2002-01-09 Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad AR032390A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75628601A 2001-01-09 2001-01-09
US09/801,925 US20020143000A1 (en) 2001-01-09 2001-03-09 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment

Publications (1)

Publication Number Publication Date
AR032390A1 true AR032390A1 (es) 2003-11-05

Family

ID=27116200

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100053A AR032390A1 (es) 2001-01-09 2002-01-09 Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad

Country Status (24)

Country Link
US (1) US20040152684A1 (enExample)
EP (1) EP1365765B1 (enExample)
JP (1) JP2004520411A (enExample)
CN (1) CN1244329C (enExample)
AR (1) AR032390A1 (enExample)
AT (1) ATE367817T1 (enExample)
AU (1) AU2002253488B2 (enExample)
BG (1) BG107977A (enExample)
BR (1) BR0206367A (enExample)
CA (1) CA2433776A1 (enExample)
CZ (1) CZ20031864A3 (enExample)
DE (1) DE60221359T2 (enExample)
DK (1) DK1365765T3 (enExample)
EE (1) EE200300321A (enExample)
ES (1) ES2290284T3 (enExample)
HR (1) HRP20030628A2 (enExample)
HU (1) HUP0302632A2 (enExample)
IL (1) IL156729A0 (enExample)
MX (1) MXPA03006156A (enExample)
NO (1) NO20033125L (enExample)
NZ (1) NZ526908A (enExample)
PL (1) PL361689A1 (enExample)
SK (1) SK8612003A3 (enExample)
WO (1) WO2002067910A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP3501533B1 (en) * 2014-12-22 2025-07-09 Ferring B.V. Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19860719A1 (de) * 1998-12-23 2000-06-29 Schering Ag Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen

Also Published As

Publication number Publication date
US20040152684A1 (en) 2004-08-05
ES2290284T3 (es) 2008-02-16
BR0206367A (pt) 2003-12-23
BG107977A (bg) 2004-08-31
IL156729A0 (en) 2004-02-08
NO20033125L (no) 2003-09-09
HK1065953A1 (en) 2005-03-11
WO2002067910A2 (en) 2002-09-06
ATE367817T1 (de) 2007-08-15
CZ20031864A3 (en) 2004-03-17
DK1365765T3 (da) 2007-10-29
DE60221359D1 (de) 2007-09-06
WO2002067910A3 (en) 2003-02-06
NZ526908A (en) 2005-07-29
CA2433776A1 (en) 2002-09-06
EP1365765A2 (en) 2003-12-03
EP1365765B1 (en) 2007-07-25
HUP0302632A2 (hu) 2003-11-28
DE60221359T2 (de) 2008-04-17
CN1496263A (zh) 2004-05-12
NO20033125D0 (no) 2003-07-08
HRP20030628A2 (en) 2005-06-30
SK8612003A3 (en) 2004-03-02
PL361689A1 (en) 2004-10-04
AU2002253488B2 (en) 2007-02-15
EE200300321A (et) 2003-10-15
JP2004520411A (ja) 2004-07-08
MXPA03006156A (es) 2003-09-16
CN1244329C (zh) 2006-03-08

Similar Documents

Publication Publication Date Title
ATE424209T1 (de) Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung
TR200300776T2 (tr) Erkeklerde cinsel organ sertleşmemesinin tedavi edilmesi ve libidonun arttırılması için yöntem.
Taskin et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis
ES2553101T3 (es) Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
CO5271697A1 (es) Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
ES2114605T3 (es) Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el.
ES2174129T3 (es) Antagonistas de la hormona de liberacion de la gonadotropina.
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
NO20073802L (no) Leuprolidacetat og acetylkolinsteraseinhibitor eller NMDA-reseptorantagonister for behandlingen av Alzheimers sykdom
MXPA03001859A (es) Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
NO982902D0 (no) FremgangsmÕte og preparatsett for Õ hindre befruktning hos hunn-pattedyr som omfatter en kombinasjon av gestagen og °strogen
BR0112659A (pt) Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo
AR032390A1 (es) Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad
YU55403A (sh) Upotreba antigestagena za inhibiciju ubrzanog endometrijumskog sazrevanja tokom lečenja neplodnosti
BR0103913A (pt) Tratamento de combinação para depressão e ansiedade
Cooke et al. The medical treatment of mild endometriosis
UY27115A1 (es) Uso de gestágenos para inhibir la maduración acelerada del endometrio durante el tratamiento de la infertilidad
AR023819A1 (es) FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
AR245824A1 (es) Equipo de ensayo para la deteccion de in vitro de las hormonas reproductoras en la corriente sanguinea de un equipo y anticuerpo hormonal para ser utilizado con dicho equipo
NZ290554A (en) Use of gonadotropin releasing hormone (GnRH) antagonist to treat the proliferation of endometrial tissue
DE602004030546D1 (de) LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.
MY121568A (en) Use of a gnrh antagonist for the preparation of a medicament for the treatment of gonadal-steroid conditions
Fisher et al. Cloprostenol-induced luteolysis in the red deer hind: the effects of age, dose, number of corpora lutea and the later stages of the oestrous cycle

Legal Events

Date Code Title Description
FB Suspension of granting procedure